| Outcomes at median 1.8 years | Rate per 1000 person-years | RRR (95% CI) | NNT (CI) | |
| Antihypertensive | Placebo | |||
| Stroke | 12 | 18 | 30% (−1 to 51) | Not significant |
| Heart failure | 5.3 | 15 | 64% (42 to 78) | 106 (87 to 162) |
| Cardiovascular event† | 34 | 51 | 33% (18 to 46) | 60 (43 to 113) |
| Death from all causes | 47 | 60 | 20% (5 to 34) | 82 (49 to 346) |
| Death from stroke | 6.5 | 11 | 39% (1 to 62) | 241 (151 to 9396) |
| Death from cardiovascular cause | 24 | 31 | 23% (−1 to 40) | Not significant |
| Death from cardiac cause | 6.0 | 8.4 | 29% (−19 to 58) | Not significant |
*Abbreviations defined in glossary. RRR, NNT, and CI calculated from data in article.
†Stroke, myocardial infarction, heart failure, or death from cardiovascular cause.
*Abbreviations defined in glossary. RRR, NNT, and CI calculated from data in article.
†Stroke, myocardial infarction, heart failure, or death from cardiovascular cause.